Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PureTech Health ( (GB:PRTC) ) has issued an announcement.
PureTech Health’s Founded Entity Celea Therapeutics is developing deupirfenidone (LYT-100), a next-generation antifibrotic designed to improve efficacy and tolerability in idiopathic pulmonary fibrosis, a rare and fatal lung disease. The company targets underserved respiratory and fibrotic conditions where existing therapies have seen limited uptake and patient adherence.
The U.S. Food and Drug Administration and European Commission have granted Orphan Drug Designation to deupirfenidone for IPF, unlocking market exclusivity and development incentives that strengthen PureTech’s and Celea’s commercial prospects in this niche market. Backed by positive Phase 2b ELEVATE IPF data showing slower lung function decline versus pirfenidone and placebo, Celea plans to secure financing and initiate the Phase 3 SURPASS-IPF head-to-head trial in 2026, positioning deupirfenidone as a potential new standard of care and enhancing PureTech’s profile in rare respiratory diseases.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £139.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall score reflects a balance of strong liquidity and promising clinical developments against challenges in profitability and technical weakness. The company’s strategic initiatives and recent positive trial results provide a cautiously optimistic outlook, but operational risks and funding uncertainties remain significant factors.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company that creates and scales drug development entities focused on serious diseases with high unmet need. Through Founded Entities such as Celea Therapeutics, it advances late-stage candidates in a capital‑efficient way, and its model has already produced multiple FDA‑approved therapies and a pipeline of novel biopharmaceuticals.
Average Trading Volume: 427,042
Technical Sentiment Signal: Strong Sell
Current Market Cap: £311.8M
Find detailed analytics on PRTC stock on TipRanks’ Stock Analysis page.